Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences Co., Ltd, a gene sequencing and diagnostic equipment developer based in Beijing, have put pen to paper on an in-depth collaboration. The two will integrate respective technologies and capabilities to set up a joint laboratory in Beijing, alongside an integrated service and supply chain covering Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia, and Shandong. In addition, the two firms plan to leverage respective advantages in genomics, ultra-sensitive proteomics, single cell space multi-omics joint detection and analysis, and high-throughput transcriptome sequencing for drug screening and research, to develop and apply high-throughput multi-omics detection and analysis technology to support drug translation, development, and clinical research. No financial details were disclosed.
Sequanta Technologies’ Services
Sequanta Technologies, focused on genomics, proteomics, and related services to support pharmaceutical clients in biomarker discovery and clinical trials, boasts a multi-omics analysis service platform, allowing for full-process services ranging from preclinical biomarker exploration to post-marketing research.
Iomics Bio’s Technology Platforms
Iomics Bio, meanwhile, is focused on the brain science and tumor sectors, and boasts technology platforms such as those for ultrasensitive protein detection, high-throughput transcriptome, and spatial proteome.-Fineline Info & Tech
